RODEN, Netherlands–(BUSINESS WIRE)–Interventional Medical Device Solutions (IMDS), a specialty catheter company developing purpose-built solutions for complex PCI, CHIP, and CTO procedures, today announced the U.S. launch of NHanceIT™, an over-the-wire, single-lumen microcatheter built on proprietary Skeleton Backbone™ technology. Engineered to improve lesion crossing in challenging coronary anatomy, NHanceIT is part of the IMDS portfolio designed to address distinct procedural challenges thr
Coronary/Structural Heart
New Study Links HFSA OMT-HF Education to Changes in Heart Failure Prescribing
New research builds on earlier findings showing HFSA’s OMT-HF program improves clinician confidence in delivering guideline directed medical therapy WASHINGTON, Sept. 10, 2026 /PRNewswire/ — New research published in the Journal of Cardiac Failure provides additional evidence that…
Medicana Uses Robot-Assisted Technology to Perform Heart Surgery Through Small Ports
Medicana Health Group’s Prof. Suat Büket, MD explains how selected bypass and heart-valve procedures can be completed without dividing the breastbone while maintaining the same surgical objective Photo: Robotic heart surgery at Medicana Health Group via FL Comms ISTANBUL, Sept. 09, 2026 (GLOBE NEWSWIRE) — For selected heart patients, complex surgery can now be performed through several small openings between the ribs rather than by dividing the breastbone. Robot-assisted cardiac surgery combines a surgeon-controlled console with high-definition three-dimensional imaging, tremor filtration and highly articulated instruments, offering a minimally invasive route to procedures that have traditionally required a full sternotomy. Prof. Suat Büket, MD, a cardiovascular surgeon at Medicana Health Group, said the most important point is often misunderstood: the robot does not perform the operation independently. “The surgeon remains in control at every stage. The system translates the surgeon’s hand movements into precise movements inside the chest. Its value lies in giving us a magnified three-dimensional view and a range of motion that is difficult to achieve with conventional instruments through a small opening,” said Prof. Büket. Photo: Prof. Suat Büket, MD via FL Comms Several small ports instead of a divided breastbone In conventional open-heart surgery, access to the heart often requires a midline incision and division of the sternum. The bone is then rejoined at the end of the operation and must heal over the following weeks, during which patients may face movement restrictions. Wound and bone-healing complications can be particularly challenging for patients with certain risk factors. In robot-assisted cardiac surgery, the surgical team can access the chest through three or four ports between the ribs, each approximately one centimetre, depending on the planned operation. A camera and the robotic instruments are introduced through these openings. The surgeon operates from a console in the operating theatre while the bedside team supports the procedure. Technology expands the surgeon’s view and reach The system’s high-definition camera provides a three-dimensional, magnified view of the operative field. Wristed instruments can bend and rotate beyond the range of the human hand, while computer-assisted tremor filtration supports steady movement. These features are designed to help the surgeon work precisely in confined anatomical spaces; they do not replace clinical judgement or the surgical team. The robot is a surgical instrument — not an autonomous decision-maker. Patient selection, operative planning and every surgical movement remain the responsibility of the trained clinical team. The surgical objective does not change Prof. Büket stressed that a minimally invasive approach should not mean a reduced operation. When robot-assisted surgery is clinically appropriate, the aim is to complete the same planned cardiac repair or revascularisation that would otherwise be performed through an open approach. “If the plan is to perform bypass grafting or repair or replace a heart valve, the objective remains the same. The difference is the route we use to reach the heart. A smaller incision must never mean an incomplete procedure,” he said. Recovery benefits depend on the right patient Avoiding sternotomy may reduce the burden of bone healing and allow some patients to return to everyday movement sooner. Smaller incisions may also reduce wound-related concerns and can offer cosmetic and psychosocial benefits. However, not every patient is a candidate. The decision depends on the planned procedure, anatomy, previous operations, vascular access and the findings of pre-operative tests. “Robotic cardiac surgery is not automatically the best option simply because the incisions are smaller,” Prof. Büket said. “The safest and most effective approach is selected after a complete assessment. Technology adds value when it is matched to the right patient, the right procedure and an experienced team.” From precision tools to connected operating rooms Robot-assisted surgery also points toward a more connected future for operating theatres. Research into remote surgical support and telesurgery continues, but current practice still depends on a trained surgical team, specialist infrastructure and direct clinical oversight. For Prof. Büket, the immediate priority is not distance but precision: using the technology available today to reduce surgical trauma without compromising the completeness or safety of the operation. About Medicana Health Group Founded in 1992, Medicana Health Group is one of Türkiye’s leading privately owned healthcare providers, operating 19 hospitals in Türkiye, the United Kingdom, and Bosnia and Herzegovina. Serving more than 5 million patients annually, including a significant international patient base, Medicana delivers multidisciplinary care across a broad range of specialties with a strong focus on clinical excellence and patient-centered service. In addition to healthcare, the Group invests in education through Medicana Education Group and Fenerbahçe University. With approximately 15,000 employees, Medicana continues to expand its international footprint while advancing sustainability through renewable energy investments and supporting Turkish sports through long-term health sponsorships. Media contact Uğur AlkaparGlobal Media Relations DirectorFL Communicationsugur@flcommunications.co.uk This press release is intended for general informational purposes. Treatment decisions must be made by qualified clinicians following an individual patient assessment. Photos accompanying this announcement are available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7b10f86c-bc1f-41a5-a99e-3a5afb79b174 https://www.globenewswire.com/NewsRoom/AttachmentNg/92e8455e-008d-4a4a-9c60-1b85de881324
Emboline Receives U.S. FDA 510(k) Clearance for Emboliner® Embolic Protection System
Clearance brings full cerebral and systemic embolic protection to patients undergoing transcatheter aortic valve replacement (TAVR) SANTA CRUZ, Calif., Sept. 9, 2026 /PRNewswire/ — Emboline, Inc., a medical technology company developing next-generation embolic protection technology,…
egnite Unveils Major CardioCare® Platform Improvements with a New UI that Enables Even Faster and Easier Access to Critical CV Data
The upgrade accelerates a health system’s capability to go from reactive to proactive cardiovascular care along guideline-directed treatment pathways ALISO VIEJO, Calif., Sept. 8, 2026 /PRNewswire/ — egnite, Inc., a healthcare AI company focused on helping clinicians identify and manage…
Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study
PHocus met its primary endpoint, demonstrating a clinically meaningful and statistically significant placebo-adjusted reduction in pulmonary vascular resistance (PVR) of -56.3% (p
Isomab presents landmark data study supporting safety of angiogenic approaches in coronary artery disease
First comprehensive systematic review provides insights into the long-term safety profile of angiogenic approaches in coronary artery disease Data shows no evidence of increased cancer or retinopathy, resolving long-standing safety questions that have limited progress across the field…
Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
CARLSBAD, Calif.–(BUSINESS WIRE)–Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner Novartis today announced that the pelacarsen Phase 3 Lp(a)HORIZON study, a pioneering cardiovascular outcomes trial, did not meet its primary endpoint of reducing the risk of cardiovascular events, a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization requiring hospitalization, compared to placebo. Consistent with previous studies, substan
InnovHeart Announces First U.S. Saturn Transseptal TMVR System Implant, Reaching 15 Patients Globally
NEWTON, Mass. and MILAN, Sept. 3, 2026 /PRNewswire/ — InnovHeart, a medical device company developing the Saturn Transseptal Transcatheter Mitral Valve Replacement (TMVR) System, today announces the successful implantation of the first U.S. patient with the Saturn system as part of the…
Cleerly Announces New Findings on How AI-QCT Plaque Measurements Relate to Long-Term Cardiovascular Risk
DENVER–(BUSINESS WIRE)– #AI–Cleerly, a leader in advanced cardiovascular imaging analysis, today announced findings from a study of 1,385 patients with suspected coronary artery disease (CAD) presented at the European Society of Cardiology (ESC) Congress 2026 in Munich. The study, titled “Temporal associations of coronary plaque burden and myocardial perfusion with clinical outcomes,” was led by Jorge Dahdal, MD, of Clínica Alemana de Santiago, Chile, and Amsterdam UMC, the Netherlands, and presen



